Results 101 to 110 of about 427 (127)

Overcoming antifungal resistance in <i>Candida albicans via</i> RNA interference: a therapeutic perspective. [PDF]

Front Cell Infect Microbiol
Mundhe AK, Rajkumari R.
europepmc   +1 more source

Antifungal and fungicide susceptibility of clinical, animal, and environmental Fusarium and Neocosmospora species from Colombia: a one-health approach. [PDF]

Sci Rep
Saenz V, Lizcano-Salas AF, Le Pape P, Celis Ramírez AM.   +3 more
europepmc   +1 more source

Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects. [PDF]

Acta Pharm Sin B
Lu X, Zhou J, Ming Y, Wang Y, He R, Li Y, Feng L, Zeng B, Du Y, Wang C.   +9 more
europepmc   +1 more source

Novel Antifungal Agents and Their Activity against <i>Aspergillus</i> Species. [PDF]

J Fungi (Basel), 2020
Vahedi-Shahandashti R, Lass-Flörl C.
europepmc   +1 more source

Synthesis and Antifungal Activity of Aminothioxanthone Derivatives [PDF]

, 2021
Joana Filipa de Olas e Sousa Martins Cardoso
core  

The Neosartorya (Aspergillus) fischeri antifungal protein NFAP2 has low potential to trigger resistance development in Candida albicans in vitro [PDF]

Bende Gábor, Bodai László, Farkas Attila, Galgóczi László Norbert, Kristóffy Zsolt, Laczi Krisztián, Marx Florentine, Papp Csaba Gergő, Rákhely Gábor, Sáringer Szabolcs, Tóth Liliána, Zsindely Nóra   +11 more
core   +1 more source

Antifungal Drugs for the Treatment of Invasive Fungal Infections-A Limited Therapeutic Toolbox Facing Growing Resistances. [PDF]

Pharmaceuticals (Basel)
Susan V, Lang M, Sabou M, Bourel-Bonnet L.   +3 more
europepmc   +1 more source

Revisiting the History of Candidiasis. [PDF]

Cureus
Tajane SB, Pawar S, Patil S.
europepmc   +1 more source